These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 9626215)
1. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ J Clin Oncol; 1998 Jun; 16(6):2150-6. PubMed ID: 9626215 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243 [TBL] [Abstract][Full Text] [Related]
3. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Millar AW; Brown PD; Moore J; Galloway WA; Cornish AG; Lenehan TJ; Lynch KP Br J Clin Pharmacol; 1998 Jan; 45(1):21-6. PubMed ID: 9489589 [TBL] [Abstract][Full Text] [Related]
4. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Primrose JN; Bleiberg H; Daniel F; Van Belle S; Mansi JL; Seymour M; Johnson PW; Neoptolemos JP; Baillet M; Barker K; Berrington A; Brown PD; Millar AW; Lynch KP Br J Cancer; 1999 Feb; 79(3-4):509-14. PubMed ID: 10027321 [TBL] [Abstract][Full Text] [Related]
5. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Rosemurgy A; Harris J; Langleben A; Casper E; Goode S; Rasmussen H Am J Clin Oncol; 1999 Jun; 22(3):247-52. PubMed ID: 10362330 [TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. Shepherd FA; Giaccone G; Seymour L; Debruyne C; Bezjak A; Hirsh V; Smylie M; Rubin S; Martins H; Lamont A; Krzakowski M; Sadura A; Zee B J Clin Oncol; 2002 Nov; 20(22):4434-9. PubMed ID: 12431965 [TBL] [Abstract][Full Text] [Related]
7. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Tierney GM; Griffin NR; Stuart RC; Kasem H; Lynch KP; Lury JT; Brown PD; Millar AW; Steele RJ; Parsons SL Eur J Cancer; 1999 Apr; 35(4):563-8. PubMed ID: 10492628 [TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. Rowinsky EK; Humphrey R; Hammond LA; Aylesworth C; Smetzer L; Hidalgo M; Morrow M; Smith L; Garner A; Sorensen JM; Von Hoff DD; Eckhardt SG J Clin Oncol; 2000 Jan; 18(1):178-86. PubMed ID: 10623708 [TBL] [Abstract][Full Text] [Related]
9. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628 [TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy. Toppmeyer DL; Gounder M; Much J; Musanti R; Vyas V; Medina M; Orlando T; Pennick M; Lin Y; Shih W; Goodin S; Rubin E Med Sci Monit; 2003 Aug; 9(8):PI99-104. PubMed ID: 12942041 [TBL] [Abstract][Full Text] [Related]
11. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. Zucker S; Wang M; Sparano JA; Gradishar WJ; Ingle JN; Davidson NE; Clin Breast Cancer; 2006 Feb; 6(6):525-9. PubMed ID: 16595036 [TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Wall L; Talbot DC; Bradbury P; Jodrell DI Br J Cancer; 2004 Feb; 90(4):800-4. PubMed ID: 14970856 [TBL] [Abstract][Full Text] [Related]
13. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Miller KD; Gradishar W; Schuchter L; Sparano JA; Cobleigh M; Robert N; Rasmussen H; Sledge GW Ann Oncol; 2002 Aug; 13(8):1220-4. PubMed ID: 12181245 [TBL] [Abstract][Full Text] [Related]
14. A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Reid AH; Protheroe A; Attard G; Hayward N; Vidal L; Spicer J; Shaw HM; Bone EA; Carter J; Hooftman L; Harris A; De Bono JS Clin Cancer Res; 2009 Aug; 15(15):4978-85. PubMed ID: 19638462 [TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Levitt NC; Eskens FA; O'Byrne KJ; Propper DJ; Denis LJ; Owen SJ; Choi L; Foekens JA; Wilner S; Wood JM; Nakajima M; Talbot DC; Steward WP; Harris AL; Verweij J Clin Cancer Res; 2001 Jul; 7(7):1912-22. PubMed ID: 11448904 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550 [TBL] [Abstract][Full Text] [Related]
17. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Bramhall SR; Hallissey MT; Whiting J; Scholefield J; Tierney G; Stuart RC; Hawkins RE; McCulloch P; Maughan T; Brown PD; Baillet M; Fielding JW Br J Cancer; 2002 Jun; 86(12):1864-70. PubMed ID: 12085177 [TBL] [Abstract][Full Text] [Related]
18. A phase II trial of marimastat in advanced pancreatic cancer. Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327 [TBL] [Abstract][Full Text] [Related]
19. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Chiappori AA; Eckhardt SG; Bukowski R; Sullivan DM; Ikeda M; Yano Y; Yamada-Sawada T; Kambayashi Y; Tanaka K; Javle MM; Mekhail T; O'bryant CL; Creaven PJ Clin Cancer Res; 2007 Apr; 13(7):2091-9. PubMed ID: 17404091 [TBL] [Abstract][Full Text] [Related]